Thermo Fisher Scientific (NYSE:TMO) Announces Earnings Results, Beats Estimates By $0.32 EPS

Thermo Fisher Scientific (NYSE:TMO) issued its earnings results on Thursday. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32, FiscalAI reports. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the firm earned $4.28 earnings per share. The business’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific updated its FY 2026 guidance to 24.930-25.330 EPS.

Here are the key takeaways from Thermo Fisher Scientific’s conference call:

• Thermo Fisher reported a strong second quarter, with revenue up 10% to $11.99 billion, adjusted EPS up 13% to $6.03, and organic revenue growth of 5% ahead of prior guidance.
• Management said customer activity strengthened across end markets, with particular momentum in pharma/biotech, plus positive growth in academic and government, industrial and applied, and diagnostics and healthcare.
• The company raised full-year 2026 guidance for both revenue and EPS, now expecting $47.4 billion-$48.1 billion of revenue and adjusted EPS of $24.93-$25.33, reflecting stronger second-half expectations.
• Several growth initiatives performed well, including Clario and filtration/separation acquisitions, which management said are integrating smoothly and contributing to higher acquisition revenue and EPS expectations for the year.
• Thermo Fisher announced it will divest its microbiology business in the third quarter, and used $1 billion of expected proceeds for share repurchases in Q2; management said the divestiture will modestly reduce 2026 revenue and EPS.

Thermo Fisher Scientific Trading Up 9.2%

TMO traded up $48.37 during midday trading on Thursday, hitting $574.83. The company’s stock had a trading volume of 2,773,719 shares, compared to its average volume of 2,310,435. The firm has a market cap of $213.62 billion, a P/E ratio of 31.60, a PEG ratio of 2.32 and a beta of 0.87. Thermo Fisher Scientific has a 52-week low of $435.27 and a 52-week high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm has a 50-day moving average price of $488.92 and a two-hundred day moving average price of $513.21.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

Insider Transactions at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Hedge funds have recently modified their holdings of the stock. Revolve Wealth Partners LLC raised its position in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. increased its position in shares of Thermo Fisher Scientific by 0.7% during the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after purchasing an additional 20 shares during the last quarter. Challenger Wealth Management grew its position in Thermo Fisher Scientific by 3.1% during the second quarter. Challenger Wealth Management now owns 735 shares of the medical research company’s stock valued at $298,000 after buying an additional 22 shares during the period. Security National Bank of Sioux City Iowa IA grew its position in shares of Thermo Fisher Scientific by 0.3% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 6,549 shares of the medical research company’s stock valued at $2,655,000 after acquiring an additional 22 shares during the period. Finally, Johnson Financial Group Inc. lifted its position in Thermo Fisher Scientific by 1.3% during the fourth quarter. Johnson Financial Group Inc. now owns 1,746 shares of the medical research company’s stock valued at $1,012,000 after purchasing an additional 22 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target on the stock. Barclays cut their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their target price for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Piper Sandler initiated coverage on Thermo Fisher Scientific in a research report on Thursday, June 11th. They issued a “neutral” rating and a $510.00 price objective on the stock. Finally, Wolfe Research started coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $602.14.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher beat Q2 expectations, posting $6.03 adjusted EPS versus the $5.71 consensus and $11.99 billion in revenue versus $11.71 billion expected, helped by stronger customer activity across end markets and continued organic growth. Article Title
• Positive Sentiment: The company also raised FY2026 guidance, now calling for EPS of $24.93 to $25.33 and revenue of $47.4 billion to $48.1 billion, both above Wall Street estimates, which suggests management is seeing a healthier operating backdrop.
• Positive Sentiment: Earlier reports noted shares rose in premarket trading after the earnings beat, reflecting investor optimism that demand is improving across Thermo Fisher’s life sciences, diagnostics, and lab equipment businesses. Article Title
• Neutral Sentiment: ImmuPharma selected Thermo Fisher’s Patheon unit to manufacture its Kapiglucagon diabetes candidate, a modest business-development win that adds some incremental contract manufacturing exposure but is unlikely to move the stock on its own. Article Title

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.